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Background: In ICU patients, glomerular filtration is often impaired, but also supraphysiological values are observed
(“augmented renal clearance”, >130 mL/min/1.73 m2). Renally eliminated drugs (e.g. many antibiotics) must be
adjusted accordingly, which requires a quantitative measure of renal function throughout all the range of clinically
encountered values. Estimation from plasma creatinine is standard, but cystatin C may be a valuable alternative.
Methods: This was a secondary analysis of renal function parameters in 100 ICU patients from two pharmacokinetic
studies on vancomycin and betalactam antibiotics. Estimated clearance values obtained by the Cockcroft-Gault
formula (eCLCG), the CKD-EPI formula (eCLCKD-EPI) or the cystatin C based Hoek formula (eCLHoek) were compared with the
measured endogenous creatinine clearance (CLCR). Agreement of values was assessed by modified Bland-Altman plots
and by calculating bias (median error) and precision (median absolute error). Sensitivity and specificity of estimates to
identify patients with reduced (<60 mL/min/1.73 m2) or augmented (>130 mL/min/1.73 m2) CLCR were calculated.
Results: The CLCR was well distributed from highly compromised to supraphysiological values (median 73.2, range
16.8-234 mL/min/1.73 m2), even when plasma creatinine was not elevated (≤0.8 mg/dL for women, ≤1.1 mg/dL for
men). Bias and precision were +13.5 mL/min/1.73 m2 and ±18.5 mL/min/1.73 m2 for eCLCG, +7.59 and ±16.8 mL/min/
1.73 m2 for eCLCKD-EPI, and -4.15 and ±12.9 mL/min/1.73 m
2 for eCLHoek, respectively, with eCLHoek being more precise
than the other two (p < 0.05). The central 95% of observed errors fell between -59.8 and +250 mL/min/1.73 m2 for
eCLCG, -83.9 and +79.8 mL/min/1.73 m
2 for eCLCKD-EPI, and -103 and +27.9 mL/min/1.73 m
2 for eCLHoek. Augmented renal
clearance was underestimated by eCLCKD-EPI and eCLHoek. Patients with reduced CLCR were identified with good specificity
by eCLCG, eCLCKD-EPI and eCLHoek (0.95, 0.97 and 0.91, respectively), but with less sensitivity (0.55, 0.55 and 0.83).
For augmented renal clearance, specificity was 0.81, 0.96 and 0.96, but sensitivity only 0.69, 0.25 and 0.38.
Conclusions: Normal plasma creatinine concentrations can be highly misleading in ICU patients. Agreement of the
cystatin C based eCLHoek with CLCR is better than that of the creatinine based eCLCG or eCLCKD-EPI. Detection and
quantification of augmented renal clearance by estimates is problematic, and should rather rely on CLCR.
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In critical care, renal function receives much attention
because deteriorations are frequently part of syndromes
such as sepsis or low-output, and often associated with
a dire prognosis [1]. Early recognition may offer the
chance of successful treatment and hopefully prevention
of progression to renal failure. For this purpose, the
diagnostic approach must be able to discriminate normal
from abnormal renal function, and to differentiate the
latter into a limited number of degrees of severity.
Despite all its drawbacks, plasma creatinine is still rec-
ommended as the primary biomarker for the evolution
of acute kidney injury [1]. Since plasma creatinine (and
other markers) can only start to rise when renal function
is already compromised, research is rather directed to-
wards identification and validation of markers of the
preceding tissue damage, e.g. of cell cycle arrest [2,3].
A separate issue is the necessity to adjust the dose of
drugs with predominantly renal elimination to renal
function. Many antibiotics, e.g. aminoglycosides, glyco-
peptides, betalactams and part of the fluoroquinolones,
fall into this category. Recommendations by the manu-
facturers usually suggest a similar approach, with one
dosing regimen for patients with „normal“ renal func-
tion, and two or three adjusted dosing regimens for pa-
tients with reduced creatinine clearance, often starting
in the range of <50-80 ml/min. It is clear that patients
with „normal“ renal function will thus exhibit a high
variability of actual antibiotic exposure.
In the ICU, three factors make this approach particu-
larly problematic. First, infections are likely to be more
severe and rather caused by less susceptible pathogens
[4]. The risk of underdosing is therefore more substan-
tial than in less severe cases. Second, some patients
without signs of renal impairment will actually not just
have a „normal“, but a supraphysiological creatinine
clearance (>130 ml/min/1.73 m2). The term „augmented
renal clearance“ has been coined for this phenomenon
few years ago [5], and its prevalence in ICU patients
without evidence of kidney injury was recently re-
ported to be up to 65% in the first week of treatment
[6]. Third, creatinine clearance is particularly difficult
to estimate in ICU patients. Estimations based on
plasma creatinine rely on the assumptions that the en-
dogenous production of creatinine is stable and can be
predicted reasonably well from patient characteristics
(e.g. age, body weight and sex for the Cockcroft-Gault
formula [7]). These assumptions are certainly ques-
tionable in ICU patients, and important discrepancies
have been shown between the available estimation for-
mulae [8-10]. Particularly, plasma creatinine concen-
trations within the normal range have been shown to
reflect creatinine clearances both considerably below
and above the normal range [6,11].Cystatin C is an alternative endogenous marker, which
is produced in a fairly constant rate by all nucleated cells
and subject to glomerular filtration only [12]. Albeit
promising and already implemented into clinical guide-
lines for chronic kidney disease [13], the value of the
latter in ICU patients is still uncertain. In the present
analysis, we compare the agreement of the estimated
clearance of the Cockcroft-Gault formula, the CKD-EPI
formula (both based on plasma creatinine), and the
Hoek formula based on plasma cystatin C with the mea-
sured endogenous creatinine clearance [7,14,15], as well
as their respective ability to detect patients with reduced
or augmented endogenous creatinine clearance.
Methods
Study design
All data presented in this analysis were obtained during
two pharmacokinetic studies on vancomycin (study 1 [16])
and piperacillin/tazobactam, meropenem or ceftazidime
(study 2; partly published in abstract form [17], manuscript
in preparation), respectively, which were conducted at the
surgical ICU of the Charité Universitätsmedizin Berlin –
Campus Benjamin Franklin (study 1 and 2) and two surgi-
cal ICUs of the Hospital of the University of Halle (study
2). The study protocols were approved by the competent
ethics committees (Berlin: EA4/113/07, EA4/029/11; Halle:
2012-95). Written informed consent for study participation
and publication of anonymised clinical data was obtained
from the patient or a legal representative. Adult patients
who were treated with one of the study drugs and were not
on renal replacement therapy were eligible for enrolment.
Besides that, no specific criteria of exclusion (e.g. diuresis
or plasma creatinine concentration) were applied.
The investigations took place when clinical conditions
with regard to hemodynamics and renal function (in
terms of vasopressor doses, fluid balance and diuresis)
were considered to be stable. Although no exact limits
were defined, patients who required a specific clinical as-
sessment (e.g. fluid challenge), further diagnostics or a
change of therapy (e.g. starting or stopping a vasopressor
or diuretic) were considered to be unstable.
In study 1 (25 patients), urine was collected for 18 hours.
During urine collection, four plasma concentrations of
creatinine (every 6 hours) and two plasma concentrations
of cystatin C (at the beginning and the end) were obtained.
The mean values were used for calculations. In study 2,
the sampling period was chosen as convenient, and plasma
creatinine and cystatin C were determined in one sample
during or at the end of the urine collection interval.
Assessment of renal function
Plasma and urine creatinine were determined by a
standardised enzymatic assay on an ADVIA 1800 chem-
istry system (ECRE_2; Siemens Healthcare Diagnostics,
Steinke et al. BMC Anesthesiology  (2015) 15:62 Page 3 of 8Eschborn, Germany). Plasma cystatin C was determined
by a particle-enhanced immunonephelometric assay on a
BN II system (N CYSC; Siemens Healthcare Diagnostics,
Eschborn, Germany).
Renal function parameters were calculated according
to the following formulae as values normalised to body
surface area (mL/min/1.73 m2):
° Measured endogenous creatinine clearance
(normalised to 1.73 m2 body surface area):
° CLCR = (urine volume × urine creatinine)/(collection
time x plasma creatinine)/BSA × 1.73
° According to Cockcroft-Gault [7] (normalised to 1.73
m2 body surface area):
° eCLCG = (140 – age x weight)/(72 x plasma
creatinine)/BSA x 1.73 x 0.85 for women
° According to the CKD-EPI formula [14]:
° eCLCKD-EPI = 141 × min(plasma creatinine/κ, 1)
α ×
max(plasma creatinine/κ, 1)-1.209 × 0.993age × 1.018
(for women)
° κ = 0.7 for women, 0.9 for men; α = -0.329 for
women, -0.411 for men
° According to the Hoek formula [15]:
° eCLHoek = (80.35/plasma cystatin C – 4.32)
° Body surface area [18]:
° BSA = 0.007184 × height0.725 × weight0.425
Units: plasma and urine creatinine in mg/dL, plasma
cystatin C in mg/L, age in years, (total body) weight in
kg, BSA in m2, height in cm.
Statistical analysis
Microsoft Excel for Mac 2011 (Microsoft Corporation,
Redmond, WA) was used for calculation of renal func-
tion parameters, GraphPad Prism version 6 for MacOSX
(GraphPad Software, La Jolla, CA) was used for statis-
tical calculations. For each estimate of clearance eCLX, a
modified Bland-Altman plot (eCLX - CLCR vs. CLCR) was
generated. (Whereas in a classical Bland-Altman plot the
x-axis shows the mean value of the compared methods,
CLCR was preferred here so that individual patients
could be identified throughout the three plots by the
identical x-value; statistical calculations are not affected
by this modification). Bias was defined as the median
error (eCLX – CLCR), and precision as the median abso-
lute error (|eCLX – CLCR|). The paired Wilcoxon test
was used to test for differences between the absolute
errors of the three estimates. Sensitivity and specificity
to detect CLCR-values of <60 or >130 mL/min/1.73 m
2
were calculated for the identical thresholds (<60or >130 mL/min/1.73 m2), and compared by Fisher’s
exact test. Receiver-operator characteristic curves (ROC)
were generated. All p-values provided are two-tailed.
Results
In total, 100 patients contributed data to this analysis
(25 from study 1 and 75 from study 2). Patient charac-
teristics are summarised in Table 1, the full data set is
available as Additional file 1. The majority of patients
had undergone previous surgery (82 patients; mostly
general surgery or neurosurgery), and were receiving the
study antibiotics for intraabdominal infections (16 patients),
nosocomial meningitis (11), nosocomial pneumonia (46) or
other indications (27). Fourty patients received one or more
vasopressors, and 61 were on mechanical ventilation on the
day of the study. In study 1, in which 4 creatinine concen-
trations were determined during the 18 hours collection
period, the median relative change between the first and
the last value was ±4%. In one patient, it was -40% (a de-
cline from 0.55 to 0.33 mg/dL), and less than ±18% in all
others. In study 2, in which the duration of urine collection
was not standardised, the median collection interval was
12 hours (range 1.92-22.75 hours), and at least 160 ml of
urine were obtained. The patients’ renal function was
spread over a wide range (CLCR 16.8-234 mL/min/1.73 m
2),
particularly at plasma creatinine concentrations below the
upper reference limit, i.e. 0.8 and 1.1 mg/dL for women
and men, respectively (Figure 1). In 42 patients CLCR
was <60 mL/min/1.73 m2, and 16 patients presented
augmented renal clearance (CLCR > 130 mL/min/1.73 m
2).
In patients who had suffered a polytrauma, an isolated
traumatic brain injury or a subarachnoid hemorrhage
(conditions associated with augmented renal clearance)
CLCR was higher (median 102 mL/min/1.73 m
2), and in 5
cases >130 mL/min/1.73 m2.
The Bland-Altman plots are shown in Figure 2. Bias of
eCLCG was +13.5 mL/min/1.73 m
2 and precision ±18.5
mL/min/1.73 m2, but excessive overestimations were
frequent, with the central 95% of observed errors falling
between -59.8 and +250 mL/min/1.73 m2. No trend was
apparent throughout the range of observed values
(Figure 2A). For eCLCKD-EPI, bias was +7.59 mL/min/
1.73 m2 and precision ±16.8 mL/min/1.73 m2 (central
95%: -83.9 – +79.8 mL/min/1.73 m2). High values of
CLCR were underestimated (Figure 2B). The same was
true for eCLHoek, for which bias and precision were
numerically lowest (-4.15 and ±12.9 mL/min/1.73 m2,
respectively; central 95%: -103 – +27.9 mL/min/
1.73 m2; Figure 2C). Absolute errors of eCLCG and
eCLCKD-EPI were not statistically different, but both
were different from that of eCLHoek (p < 0.05).
The sensitivity to detect low values of CLCR
(<60 mL/min/1.73 m2) was identically low for eCLCG
and eCLCKD-EPI, and significantly better (p < 0.01) for




Age (years) 66 57-74 21-85
Total body weight (kg) 78 70-90 42-125
Body height (cm) 170 165-175 138-190
BMI (kg/m2) 26.2 23.1-30.3 16.0-41.5
Length of hospitalisation (days) 16 10-27 2-95
Creatinine (mg/dL) 0.75 0.50-1.20 0.15-2.83
Cystatin C (mg/L) 1.12 0.76-1.73 0.50-4.21
CLCR (mL/min/1.73 m
2) 73.2 46.8-107 16.8-234
eCLCG (mL/min/1.73 m
2) 85.2 58.7-137 22.4-462
eCLCKD-EPI (mL/min/1.73 m
2) 87.2 59.4-108 16.7-196
eCLHoek (mL/min/1.73 m
2) 67.3 42.2-101 14.8-156
APACHE II 18 13-23 5-33
SOFA 6 3-8 0-19
CLCR: measured endogenous creatinine clearance; eCLCG, eCLCKD-EPI, eCLHoek:
estimated clearance by the Cockcroft-Gault, CKD-EPI or Hoek formula; APACHE
II: acute physiology and chronic health evaluation II score. SOFA: sequential


















Figure 1 Measured creatinine clearance (CLCR) vs. plasma creatinine. Data
studies on antibiotics. The inlet shows the distribution of the 63 patients w
(0.8 mg/dL for women, 1.1 mg/dL for men; vertical dotted lines).
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Patients with augmented renal clearance (>130 mL/
min/1.73 m2) were identified with the highest sensitiv-
ity by eCLCG, but specificity was significantly lower
than that of the other two (p < 0.01; Table 2). The
ROC curves both for low and high CLCR showed a
slightly higher discriminative power (in terms of AUC)
for eCLHoek than for eCLCG and eCLCKD-EPI (Figure 3).
Since the variable duration of urine collection could
have influenced the results, subsets were reanalysed
which included only the patients of study 1 (n = 25), or
all patients in which urine was collected for at least
12 hours (n = 66) or less than 8 hours (n = 31). The re-
sults did not show any relevant differences compared to
the complete data set (Additional file 2).Discussion
With the present study, we provide data on the agreement
of estimates of renal function based on plasma creatinine
or cystatin C with measured endogenous creatinine clear-
ance in ICU patients. In accordance with other studies
[6,11], we observed extreme values of measured endogen-
ous creatinine clearance in patients with plasma creatinine
concentrations below the upper reference limit (≤0.8 mg/






















were obtained from 100 ICU patients participating in pharmacokinetic
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Figure 2 Agreement of estimated with measured creatinine
clearance (CLCR) in 100 ICU patients. Estimation was done by (A) the
Cockcroft-Gault formula (eCLCG), (B) the CKD-EPI formula (eCLCKD-EPI),
or (C) the Hoek formula (eCLHoek). Bold line: LOWESS curve. Horizontal
solid line: median; dashed lines: 25th/75th percentile; dotted lines: 2.5th/
97.5th percentile of observations. Note the larger scale of the y-axis in
figure A.
Steinke et al. BMC Anesthesiology  (2015) 15:62 Page 5 of 8need for a more reliable quantification of renal function in
this population.
Although the bias of all three estimates appeared ac-
ceptable, it is obvious that their precision is limited and
may be completely misleading with regard to the actual
renal function. Both creatinine based estimates tended
to overestimate low or normal CLCR-values, which was
also reflected by a low sensitivity to detect patients with
reduced renal function. In this range, the cystatin C
based Hoek formula was significantly more precise, and
notably more sensitive with similar specificity. A plaus-
ible explanation for this is that cystatin C does not de-
pend on muscle mass, unlike creatinine. All three
formulae were derived from non-critically ill popula-
tions, and imply certain relationships between measures
of body size (weight or BSA) and the production of
cystatin C or creatinine. Loss of muscle mass due to im-
mobilisation and catabolism is certainly a prominent fea-
ture in many critically ill patients, and necessarily affects
the accuracy of creatinine based estimates. Cystatin C
might therefore offer an advantage for assessing renal
function both in clinical routine and research, when a
timed urine collection or the clearance of an exogenous
marker is not available. However, its exact significance
must be further explored and defined, also to justify the
much higher costs (in our institution ca. 10€ per deter-
mination compared with 0.50€ for creatinine). Although
there are several reports on cystatin C-guided therapy
with vancomycin or aminoglycosides [19-22], such infor-
mations are generally lacking for most drugs. Further
open issues are the availability of standardised commer-
cial assays, and confounding effects of various disease
states. In contrast to initial reports, the production of
cystatin C is not entirely constant either [12,23]. In the
context of critical care, particularly inflammation, gluco-
corticoids and dysthyroid states could influence its levels,
but also preexisting conditions such as obesity and smok-
ing. Unfortunately, these confounding conditions were not
assessed in our study, but given their rather generic nature
it appears safe to assume that many patients with one or
more of these conditions were represented in the study.
Baptista and colleagues made similar observations in
54 critically ill patients [9]. Although patients with
plasma creatinine >1.3 mg/dL were excluded, 8 h-CLCR
ranged from 16.2 to 378.3 mL/min/1.73 m2, and the
Cockcroft-Gault, the MDRD and the CKD-EPI formulae
Table 2 Sensitivity and specificity (95% confidence
intervals) to detect reduced or augmented endogenous
creatinine clearance
CLCR <60 mL/min/1.73 m
2 CLCR >130 mL/min/1.73 m
2
sensitivity specificity sensitivity specificity
















CLCR: measured endogenous creatinine clearance; eCLCG, eCLCKD-EPI, eCLHoek:
estimated clearance by the Cockcroft-Gault, CKD-EPI or Hoek formula.
*different from eCLCG and eCLCKD-EPI (p < 0.01).
**different from eCLCKD-EPI (p < 0.05).
***different from eCLCKD-EPI and eCLHoek (p < 0.01).












eCLHoek AUC = 0.94 (0.89-0.98)
eCLCKD-EPI AUC = 0.86 (0.78-0.95)
eCLCG AUC = 0.87 (0.79-0.94)
A












eCLHoek AUC = 0.92 (0.86-0.98)
eCLCKD-EPI AUC = 0.86 (0.79-0.94)
eCLCG AUC = 0.86 (0.78-0.93)
B
Figure 3 Receiver-operator characteristic curves for detection of
reduced (A; CLCR < 60 mL/min/1.73 m
2) or augmented renal
clearance (B; CLCR > 130 mL/min/1.73 m
2). AUC area under the
curve (95%-confidence interval).
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and colleagues compared the reciprocals of plasma
cystatin C and creatinine with 24 h-CLCR in 50 critically
ill patients at risk for developing acute renal failure, and
reported a much stronger correlation for 1/cystatin C
than for 1/creatinine [24]. Recently, Delanaye and col-
leagues reported data from a study in 47 critically ill pa-
tients, in which a true gold standard, iohexol clearance,
was used [25]. Cystatin C was superior to creatinine to
detect patients with GFR <60 mL/min, but patients with
a plasma creatinine concentration >1.5 mg/dL were ex-
cluded from the study. In general, our results agree with
these previous findings, but significantly extend the body
of evidence in a large cohort (n = 100) of unselected
(with regard to renal function) ICU patients.
Of concern is the lack of agreement of any of the three
formulae with high CLCR-values, and their low sensitivity
to detect patients with augmented renal clearance (CLCR >
130 mL/min/1.73 m2), who are at risk for inappropriately
low drug concentrations, e.g. of antibiotics. This again
calls to mind that none of the formulae was designed for
critically ill patients, but rather for detection and follow-
up of chronic renal disease. When augmented renal
clearance is suspected, it seems advisable to rely on the
endogenous creatinine clearance rather than on estimates.
Several limitations must be mentioned. Our data were
extracted as a secondary analysis from pharmacokinetic
studies on renally eliminated antibiotic agents. Reliable
quantification of renal function was therefore an import-
ant feature of the study designs, but some aspects were
neglected, which would be necessary for a more thor-
ough assessment of renal function parameters in critic-
ally ill patients. For one, renal function in critically ill
patients is certainly dynamic. Glomerular filtration (as
only the most important part of “renal function” in the
context of drug dosing) can rapidly change due to e.g.
hemodynamic alterations or systemic inflammation, two
common events in ICU patients. Patients’ conditionswere clinically judged to be “stable”, but more formal cri-
teria (e.g. for vasopressor doses, fluid balance or urine out-
put) would have been preferable. Second, the length of the
urine collection periods were quite variable between pa-
tients, being only ~2 hours in some cases. Although such
short periods have been reported to adequately substitute
longer intervals (24 hours) [26], the results would be easier
to interprete if a uniform protocol had been used for all pa-
tients, even if our sensitivity analysis did not show an
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dogenous creatinine clearance is also only an approxima-
tion of glomerular filtration. Besides free glomerular
filtration, it is also subject to tubular secretion which be-
comes quantitatively more important when GFR decreases
[27]. Tubular secretion of creatinine may be differentially
affected by chronic or acute renal disease, and can be inhib-
ited by a number of drugs (e.g. trimethoprim and cimeti-
dine), which leads to a lower endogenous creatinine
clearance despite constant GFR [27]. (In fact, blocking
tubular secretion of creatinine by coadministration of ci-
metidine has been suggested as a mean to improve the ac-
curacy of endogenous creatinine clearance measurements
[28].) Cimetidine is not in use in the participating ICUs,
and sulfamethoxazole-trimethoprim is administered only
rarely (for prevention or treatment of Pneumocystis jirovecii
infections); the prevalence of specific chronic disease (e.g.
glomerulonephritis) was certainly minimal in our popula-
tion of surgical ICU patients, whereas both degenerative
loss of renal function and acute kidney injury probably
accounted for the large part of patients with reduced CLCR.
Unfortunately, however, a more detailed analysis is not pos-
sible because these informations were not systematically re-
corded. The use of a true gold standard, i.e. clearance of an
exogenous marker such as inulin or iothalamate, would cer-
tainly have been desirable, but is unlikely to be done in clin-
ical routine or on a large scale in clinical studies. As a
compromise of validity and practicability, the use of en-
dogenous creatinine clearance as reference, as done in the
present study, seems therefore justified.
Conclusions
We assessed the agreement of the Cockcroft-Gault formula,
the CKD-EPI formula (both based on plasma creatinine)
and the Hoek formula (based on cystatin C) with measured
creatinine clearance in a comparatively large and unselected
cohort of surgical ICU patients. In accordance with previ-
ous findings, extreme values of creatinine clearance were
observed in patients with plasma creatinine concentrations
below the upper reference limit. The Hoek formula was sig-
nificantly more precise than the other two formulae. The
value of cystatin C for clinical decision making and to guide
drug dosing in ICU patients should be further defined (e.g.
by inclusion in pharmacokinetic studies), before it may find
a role in clinical routine. However, identification and quan-
tification of augmented renal clearance without urine col-
lection remains problematic.
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